EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

GLP-1 and the Neurobiology of Eating Control: Recent Advances

Lauren A Jones iD, Daniel I Brierley iD

Endocrinology · 2025-01-06 · 166 (2)

DOI: 10.1210/endocr/bqae167 ↗

At a glance

Übersichtsarbeit in Endocrinology, published online on 2025-01-15. Written by Lauren A Jones and 1 co-authors. Institution: Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E…. Major MEDLINE topics: Glucagon-Like Peptide 1, Obesity, Eating, Appetite Regulation. Cited 47 times so far (Crossref); 137 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Wellcome Trust.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterized by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening. However, the field of obesity pharmacotherapy has now entered a new era of AOMs based on analogues of the gut hormone and neuropeptide glucagon-like peptide-1 (GLP-1). The latest versions of these drugs elicit unprecedented levels of weight loss in clinical trials, which are now starting to be substantiated in real-world usage. Notably, these drugs reduce weight primarily by reducing energy intake, via activation of the GLP-1 receptor on multiple sites of action primarily in the central nervous system, although the most relevant sites of action, and the neural circuits recruited remain contentious. Here we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies which have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide 1ObesityEatingAppetite RegulationHumansAnimalsAnti-Obesity AgentsGlucagon-Like Peptide-1 ReceptorSignal Transduction

Author keywords

GLP-1eatingfeedingglucagon-like peptide-1liraglutideobesitysemaglutide

Substances

Glucagon-Like Peptide 1Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor

Authors and institutions

  • Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6DE, UK.

ORCID profiles: Lauren A Jones, Daniel I Brierley

Funding

  • Wellcome Trust

Cite

APA

Jones, L. A., & Brierley, D. I. (2025). GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology, 166(2). https://doi.org/10.1210/endocr/bqae167

Vancouver

Jones LA, Brierley DI. GLP-1 and the Neurobiology of Eating Control: Recent Advances. Endocrinology. 2025;166(2). doi:10.1210/endocr/bqae167

BibTeX
@article{Jones2025,
  author = {Jones, Lauren A and Brierley, Daniel I},
  title = {GLP-1 and the Neurobiology of Eating Control: Recent Advances},
  journal = {Endocrinology},
  year = {2025},
  volume = {166},
  number = {2},
  doi = {10.1210/endocr/bqae167}
}
Start for free →